Association Between Homocysteinemia and Mortality in CKD: A Propensity-score Matched Analysis Using NHANES-National Death Index

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2022 Sep 10

PMID 36086712

Authors

Je Hun Song

Hyuk Huh

Eunjin Bae

Jeonghwan Lee

Jung Pyo Lee

Jong Soo Lee

Gwang Sil Kim

Kyung Don Yoo

Affiliations

Soon will be listed here.

Abstract

Hyperhomocysteinemia (HHcy) is considered a risk factor for cardiovascular disease (CVD), including chronic kidney disease (CKD). In this study, we investigated the association between levels of serum homocysteine (Hcy) and mortality, inferred from the presence of CKD. Our study included data of 9895 participants from the 1999 to 2016 National Health and Nutrition Examination Surveys (NHANES). Multivariable-adjusted Cox proportional hazard models using propensity-score, were used to examine dose-response associations between Hcy level and mortality. A total of 9895 participants, 1025 (10.3%) participants were diagnosed with CKD. In a multivariate Cox regression analysis including all participants, Hcy level was significantly associated with all-cause mortality in the nonCKD group, compared to the 1st quartile in the fully adjusted model (2nd quartile: hazard ratio (HR) 1.75, 95% confidence interval (CI) 1.348-2.274, P < .001; 3rd quartile: HR 2.22, 95% CI 1.726-2.855, P < .001; 4th quartile: HR 3.77, 95% CI 2.952-4.830, P < .001). However, this finding was not observed in the CKD group. The observed pattern was similar after propensity score matching. In the nonCKD group, overall mortality increased in proportion to Hcy concentration (2nd quartile: HR 2.19, 95% CI 1.299-3.709, P = .003; 3rd quartile: HR 2.60, 95% CI 1.570-4.332, P < .001; 4th quartile: HR 3.72, 95% CI 2.254-6.139, P < .001). However, the risk of all-cause mortality according to the quartile of Hcy level, did not increase in the CKD group. This study found a correlation between the Hcy level and mortality rate only in the nonCKD group. These altered risk factor patterns may be attributed to protein-energy wasting or chronic inflammation status, that is accompanied by CKD.

Citing Articles

The Association of Plasma Homocysteine Concentrations with a 10-Year Risk of All-Cause and Cardiovascular Mortality in a Community-Based Chinese Population.

Liang Z, Li K, Chen H, Jia J, Li J, Huo Y Nutrients. 2024; 16(12).

PMID: 38931298 PMC: 11206274. DOI: 10.3390/nu16121945.

References

Suliman M, Lindholm B, Barany P, Qureshi A, Stenvinkel P . Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial. 2007; 20(6):523-9. DOI: 10.1111/j.1525-139X.2007.00336.x. View

Yang Q, Lu Y, Deng Y, Xu J, Zhang X . Homocysteine level is positively and independently associated with serum creatinine and urea nitrogen levels in old male patients with hypertension. Sci Rep. 2020; 10(1):18050. PMC: 7581807. DOI: 10.1038/s41598-020-75073-x. View

Bulbul M, Dagel T, Afsar B, Ulusu N, Kuwabara M, Covic A . Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purif. 2018; 46(2):144-152. DOI: 10.1159/000488816. View

Klag M, Ford D, Mead L, He J, Whelton P, Liang K . Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993; 328(5):313-8. DOI: 10.1056/NEJM199302043280504. View

Park J . Kidney disease and obesity paradox. Kidney Res Clin Pract. 2017; 36(1):1-2. PMC: 5331969. DOI: 10.23876/j.krcp.2017.36.1.1. View

Moon H, Ko H, Kim A . Hyperhomocysteinemia Concurrent with Metabolic Syndrome Is Independently Associated with Chronic Kidney Disease among Community-Dwelling Adults in an Urban Korean Population. Int J Environ Res Public Health. 2020; 17(18). PMC: 7558526. DOI: 10.3390/ijerph17186810. View

Suliman M, Stenvinkel P, Qureshi A, Kalantar-Zadeh K, Barany P, Heimburger O . The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant. 2006; 22(1):209-17. DOI: 10.1093/ndt/gfl510. View

Yap S, Naughten E, Wilcken B, Wilcken D, Boers G . Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost. 2000; 26(3):335-40. DOI: 10.1055/s-2000-8100. View

. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994; (32):1-407. View

10.

Bostom A, Lathrop L . Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52(1):10-20. DOI: 10.1038/ki.1997.298. View

11.

Weiner D, Tighiouart H, Amin M, Stark P, MacLeod B, Griffith J . Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15(5):1307-15. DOI: 10.1097/01.asn.0000123691.46138.e2. View

12.

Collins S, Myatt M . Short-term prognosis in severe adult and adolescent malnutrition during famine: use of a simple prognostic model based on counting clinical signs. JAMA. 2000; 284(5):621-6. DOI: 10.1001/jama.284.5.621. View

13.

Jamison R, Hartigan P, Kaufman J, Goldfarb D, Warren S, Guarino P . Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298(10):1163-70. DOI: 10.1001/jama.298.10.1163. View

14.

Yap S, Boers G, Wilcken B, Wilcken D, Brenton D, Lee P . Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001; 21(12):2080-5. DOI: 10.1161/hq1201.100225. View

15.

Zhou J, Austin R . Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors. 2009; 35(2):120-9. DOI: 10.1002/biof.17. View

16.

Suliman M, Stenvinkel P, Heimburger O, Barany P, Lindholm B, Bergstrom J . Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis. 2002; 40(3):480-8. DOI: 10.1053/ajkd.2002.34887. View

17.

Suliman M, Stenvinkel P, Qureshi A, Barany P, Heimburger O, Anderstam B . Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis. 2004; 44(3):455-65. View

18.

Qureshi A, Alvestrand A, Divino-Filho J, Gutierrez A, Heimburger O, Lindholm B . Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13 Suppl 1:S28-36. View

19.

Friedman E . Selection bias impacts outcome reports of uremia therapy. Am J Kidney Dis. 2000; 36(1):208-10. DOI: 10.1053/ajkd.2000.8927. View

20.

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View